ASSESSMENT OF THE PNEUMOCOCCAL VACCINATION PROGRAMME IN MANGISTAU REGION, KAZAKHSTAN


Cite item

Full Text

Abstract

Pneumonia is one of the main contributors to infant mortality in Kazakhstan. In 2010, Kazakhstan became the first former Soviet republic introduced pneumococcal vaccine into the national immunization scheme. Mangistau region was one of the two first regions where the vaccination became routine from 1 December 2010 using a WHO certified PCV-13 vaccine. The aims of this study were: 1) to assess the number of hospitalizations of children aged 0-5 years for pneumonia in the region before and after introduction of vaccination programme; 2) to compare duration of hospital stay of children with pneumonia before and after introduction of vaccination programme and 3) to compare time between the first visit to medical services and hospitalization of children with pneumonia before and after introduction of vaccination programme. Data to answer these three research questions were analyzed using multivariable negative binomial regression, multiple linear regression and multivariable logistic regression, respectively. All coefficients and odds ratios (OR) are presented with 95 % confidence intervals (CI). We observed a significant reduction of the number of cases of pneumonia by 22 (95 % CI: 6-38) % in 2011 and by 33 (95 % CI: 16-49) % in 2012 compared to 2009. No changes in the duration of hospital stay (β = 0.28; 95 % CI: -0.06; 0.64) or the number of days (0-6 vs. 7 days or more) between the first contact with the healthcare system (OR = 1.0; 95 % ДИ: 0.8-1.2) and hospitalization were found. Our results suggest that the introduction of vaccination against pneumococcal infection contributed to the overall reduction of the number of cases of pneumonia among children aged 0-5 years in Mangistau region, Kazakhstan.

About the authors

I K Karibayeva

National Kazakh Medical University named after. S.D. Asfendiyarov

G E Aimbetova

National Kazakh Medical University named after. S.D. Asfendiyarov

S A Amireev

National Kazakh Medical University named after. S.D. Asfendiyarov

L T Yeraliyeva

National Kazakh Medical University named after. S.D. Asfendiyarov

A D Kyzayeva

National Kazakh Medical University named after. S.D. Asfendiyarov

A A Akanov

National Kazakh Medical University named after. S.D. Asfendiyarov

K A Tulebayev

National Kazakh Medical University named after. S.D. Asfendiyarov

B C Turdaliyeva

National Kazakh Medical University named after. S.D. Asfendiyarov

A M Grjibovski

Norwegian Institute of Public Health; International School of Public Health, Northern State Medical University; International Kazakh-Turkish University

Email: andrej.grjibovski@gmail.com
старший советник Норвежского института общественного здравоохранения, г. Осло, Норвегия; директор Архангельской международной школы общественного здоровья СГМУ, г. Архангельск; профессор Международного казахско-турецкого университета

References

  1. Государственная программа развития здравоохранения Республики Казахстан «СаламаттыКазакстан» на 2011 - 2015 годы: Указ Президента Республики Казахстан от 29 ноября 2010 года № 1113. URL: http://online.zakon.kz/document/?doc_id=30861087 [дата обращения: 17.12.2014]
  2. Инфекции респираторного тракта у детей раннего возраста / под ред. Г.А. Самсыгиной. М.: Миклош, 2006. С. 187-250.
  3. Рациональная фармакотерапия детских заболеваний: руководство для практикующих врачей в 2 кн. / под общ. ред. А.А. Баранова, Н.Н. Володина, Г.А. Самсыгиной. М.: Литтерра, 2007. С. 451-468.
  4. Рекомендации расширенного заседания Совета экспертов на тему «Бремя пневмококковых заболеваний в России» // Вопросы современной педиатрии. 2009. Т. 8, № 2. C. 104 - 109.
  5. Сидоренко С.В., Лобзин Ю.В., Харит С.М., Королева И.С., Таточенко В.К. Пневмококковая инфекция и современные возможности ее профилактики - эпидемиологический обзор ситуации в мире и в России // Вопросы современной педиатрии. 2010. Т. 9, № 1. С. 54-61.
  6. Статистический сборник «Здоровье населения Республики Казахстан и деятельность организаций здравоохранения в 2008 году». Астана, 2009.
  7. Aguiar S.I., Brito M.J., Horacio A.N., Lopes J.P., Ramirez M., Melo-Cristino J. Decreasing incidence and changes in serotype distribution of invasive pneumococcal disease in persons aged under 18 years since introduction of 10-valent and 13-valent conjugate vaccines in Portugal, July 2008 to June 2012 // Euro Surveill. 2014. Vol. 27. Р. 20750.
  8. American Academy of Pediatrics. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23) // Pediatrics. 2010. Vol. 126. P. 186-190.
  9. Buckingham S.C. Incidence and etiologies of complicated pneumonic effusion in children 1996-2001 // Pediatr. Infect. Dis. J. 2003. Vol. 22. P. 499-504.
  10. Caierão J., Hawkins P., Santanna F.H., da Cunha G.R., d'Azevedo P.A., McGee L., Dias C. Serotypes and Genotypes of Invasive Streptococcus pneumoniaeBefore and After PCV10 Implementation in Southern Brazil // PLoS One. 2014. Vol. 30. e111129.
  11. Centers for Disease Control and Prevention. Progress in introduction of pneumococcal conjugate vaccine-worldwide, 2000-2008. MMWR Morb Mortal // Wkly Rep. 2008. Vol. 57. P. 1148-1151.
  12. De Wals P., Lefebvre B., Markowski F., Deceuninck G., Defay F., Douville-Fradet M., Landry M. Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada // Vaccine. 2014. Vol. 32. P. 1501-1506.
  13. Juven T., Mertsola J., Waris M. et al. Etiology of community-acquired pneumonia in 254 hospitalized children // Pediatr. Infect. Dis. J. 2000. Vol. 19. P. 293-296.
  14. Lebel M.H., Kellner J.D., Ford-Jones E.L., et al. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada // Clin. Infect. Dis. 2003. Vol. 36. P. 259-268.
  15. Lieu T.A., Ray G.T., Black S.B. et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children // JAMA. 2000. Vol. 283. P. 1460-1468.
  16. Lloyd A., Patel N., Scott D.A., Runge C., Claes C., Rose M. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects // Eur. J. Health Econ. 2008. Vol. 9. P. 7-15.
  17. Ndlangisa K.M., du Plessis M., Wolter N., de Gouveia L., Klugman K.P., von Gottberg A. GERMS-SA. Population snapshot of Streptococcus pneumoniae causing invasive disease in South Africa prior to introduction of pneumococcal conjugate vaccines // PLoS One. 2014. Vol. 9. e107666.
  18. Poehling K.A., Talbot T.R., Griffin M.R., Craig A.S., Whitney C.G., Zell E. et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine // JAMA. 2006. Vol. 295. P. 1668-1674.
  19. Robinson K.A., Baughman W., Rothrock G., Barrett N.L., Pass M., Lexau C. et al. Active Bacterial Core Surveillance (ABCs) Emerging Infections Program Network. Epidemiology of invasive Streptococcus pneumoniaeinfections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era // JAMA. 2001. Vol. 285. P. 1729- 1735.
  20. Sinha A., Levine O., Knoll M.D., Muhib F., Lieu T.A. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis // Lancet. 2007. Vol. 369. P. 389-396.
  21. Tsigrelis C., Tleyjeh I.M., Huskins W.C., Lahr B.D., Nyre L.M., Virk A., Baddour L.M. Incidence of invasive pneumococcal disease among children after introduction of a 7-valent pneumococcal conjugate vaccine: a population-based study in Olmsted County, Minnesota // Mayo Clin. Proc. 2009. Vol. 84. P. 871- 875.
  22. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper // Wkly Epidemiol Rec. 2007. Vol. 82. P. 93-104.

Copyright (c) 2015 Human Ecology


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies